NEW ORLEANS, LA – Congratulations to Dr. Patrick Dennis and the exceptional clinical research team at Touro Medical Center for achieving the first site activated, first patient screened, and enrolled in a global Phase IIb clinical trial. This trial evaluates for the treatment of patients suffering from age-related primary moderate-to-severe knee osteoarthritis (KOA).

Securing both the first site activation, screening, and enrollment simultaneously is a major milestone. This accomplishment highlights the site’s outstanding operational preparedness, robust community integration, and dedication to advancing cutting-edge therapeutic alternatives for debilitating musculoskeletal diseases.

As a long-standing Principal Investigator within the DelRicht Research site network, Dr. Patrick Dennis brings extensive clinical experience and a proven history of execution to this study. Operating out of Touro Medical Center in New Orleans, Dr. Dennis has led more than 100 clinical trials across a variety of high-need therapeutic areas, including:

– Chronic pain management

– Musculoskeletal disorders

– Cardiometabolic health

– Late-phase vaccine development

Dr. Dennis is highly regarded for his adherence to rigorous protocol standards, high data integrity, and consistent enrollment success. His focus on balancing scientific accuracy with patient-centered advocacy ensures that complex protocols are executed seamlessly.

Operational Excellence: The Sponsor and CRO Advantage

For sponsors and CROs managing competitive global timelines, study startup efficiency and enrollment velocity are critical metrics for mitigating trial risk.

Dr. Dennis’s team has established strong enrollment momentum. This clinical readiness directly helps sponsors safeguard their development timelines, reduce overall study cycle times, and accelerate the transition from clinical pipeline to patient care. Tyler Hastings, Managing Partner at DelRicht Research added:

“Securing both the first site activation, first patient screened, and randomized in a highly competitive, global Phase IIb trial is a testament to top-tier site readiness,” said Tyler Hastings, Managing Partner at DelRicht Research. “Timelines are everything in mid-stage clinical development. Dr. Dennis’s leadership and his team’s operational precision are exactly why sponsors trust the DelRicht network to execute their critical protocols efficiently.”

 

– Tyler Hastings, Managing Partner at DelRicht Research

By initiating enrollment ahead of schedule, the New Orleans research team provides clinical momentum for a global trial development strategy. Simultaneously, it offers local patients early access to next-generation immunotherapies that could redefine the future standard of care for osteoarthritis. DelRicht Research remains dedicated to partnering with leading investigators like Dr. Dennis, who combine clinical excellence with the operational speed required to advance modern medicine.

About DelRicht Research

DelRicht Research is a nationwide, multi-specialty site network dedicated to increasing patient participation in clinical trials. By partnering with independent physicians across a wide range of therapeutic specialties, DelRicht delivers high-quality, scalable clinical research while maintaining a community-centered approach to trial access. Through centralized operations and expert site management, DelRicht optimizes study recruitment and data collection for biotechnology and pharmaceutical sponsors worldwide.

Learn more about our current studies in orthopedic and osteoarthritis research.